$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
复发性卵巢癌治疗重大突破:尼拉帕尼延长铂类敏感型癌症的无进展生存期
2025-10-19 11:44:20
Check Details
奥拉帕尼上市,国内卵巢癌患者的福音
2025-10-19 11:44:20
Check Details
尼拉帕尼治疗复发性卵巢癌的长期获益
2025-10-19 11:44:20
Check Details
尼拉帕尼治疗复发性卵巢癌患者
2025-10-19 11:44:20
Check Details
奥拉帕尼常见的不良反应
2025-10-19 11:44:20
Check Details
尼拉帕尼显著改善卵巢癌患者生存期
2025-10-19 11:44:20
Check Details
卡博替尼适应症之卵巢癌
2025-10-19 11:44:20
Check Details
多吉美抗肿瘤治疗之卵巢癌
2025-10-19 11:44:20
Check Details
奥拉帕尼获批的适应症
2025-10-19 11:44:20
Check Details
欧盟批准奥拉帕尼BRCA突变卵巢癌患者
2025-10-19 11:44:20
Check Details
奥拉帕尼复发性卵巢癌患者新希望
2025-10-19 11:44:20
Check Details
PARP抑制剂引发卵巢癌范式的最大转变
2025-10-19 11:44:20
Check Details
1
2
...
761
762
763
764
765
766
767
...
4153
4154
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Elacestrant: Precision Therapy for ESR1-Mutant Resistant HR+/HER2- Advanced Breast Cancer
2
Selpercatinib Complete Medication Guide: Indications, Dosage and Safety Information for RET Inhibitor
3
Complete Guide to Dosage and Dose Adjustment of Entrectinib
4
Comprehensive Analysis of Bleeding Risk with Tepotinib in MET-Mutated Non-Small Cell Lung Cancer
5
Lomustine vs Temozolomide: Comprehensive Comparison of Efficacy and Safety in Glioma Treatment
6
Tepotinib and Osimertinib: Current Status and Clinical Positioning of Combination Therapy in Non-Small Cell Lung Cancer
7
Tumor Shrinkage Effect and Core Therapeutic Value of Pazopanib
8
Tabrecta (Capmatinib): A Targeted Therapy for METex14-Mutated NSCLC
9
Pazopanib Shows Promise as Second-Line Therapy for Aggressive Skin Cancer
10
Managing Immunotherapy-Related Adverse Events of Tarlatamab-Imdelltra: A Guide to Dual-Specific T Cell Engager Safety
11
Almonertinib Safety Guide: Managing Adverse Reactions in NSCLC Treatment with a 3rd-Gen EGFR TKI
12
Pimitespib Storage Guidelines: Temperature, Humidity & Light Control for Home Use